
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in doubt about this circular or as to the action to be taken, you should consult your stockbroker, or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Cryofocus Medtech (Shanghai) Co., Ltd.**, you should at once hand this circular with the enclosed proxy form to the purchaser or transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



Cryofocus Medtech (Shanghai) Co., Ltd.
康豐生物科技（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

- (1) WORK REPORT OF THE BOARD FOR 2025;**
(2) PROFIT DISTRIBUTION PLAN FOR 2025;
(3) AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR 2025;
(4) 2025 ANNUAL REPORT;
(5) REMUNERATION OF DIRECTORS;
(6) RE-APPOINTMENT OF AUDITORS FOR 2026;
(7) GENERAL MANDATE TO ISSUE SHARES;
AND
(8) NOTICE OF THE AGM

Capitalized terms used on this cover page shall have the same meanings as those defined in this circular.

The Company will convene and held the AGM at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC on Friday, June 5, 2026 at 10:00 a.m., the notice of which is set out on pages 10 to 14 of this circular. The proxy form for use at the AGM is enclosed herein, which is also published on the website of the Stock Exchange (www.hkexnews.hk).

If you intend to attend the AGM by proxy, you are required to duly complete the accompanying proxy form according to the instructions printed thereon and return the same not less than 24 hours before the time fixed for the holding of the AGM or any adjournment thereof (as the case may be) (which is 10:00 a.m. on Thursday, June 4, 2026 (or other date in the event of any adjournment thereof)). Completion and return of the proxy form will not preclude you from attending and voting in person at the AGM or any adjournment thereof if you so wish.

References to times and dates in this circular are to Hong Kong local times and dates.

April 28, 2026

CONTENTS

	<i>Pages</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
NOTICE OF THE AGM	10

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“2025 Annual Report”	the annual report of the Company for the year ended December 31, 2025, which is published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.cryofocus.com)
“AGM”	the 2025 annual general meeting of the Company to be held at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC at 10:00 a.m. on Friday, June 5, 2026 or any adjournment thereof for the purpose of, considering and, if thought fit, approving the resolutions contained in the notice of the AGM as set out on pages 10 to 14 of this circular
“Articles of Association”	the articles of association of the Company currently in force
“Board”	the board of Directors
“Company”	Cryofocus Medtech (Shanghai) Co., Ltd. (康澧生物科技(上海)股份有限公司), a joint stock company incorporated in the PRC with limited liability on July 21, 2021, or, where the context requires (as the case may be), its predecessor, Cryofocus Medtech (Shanghai) Company Limited (康澧生物科技(上海)有限公司), a limited liability company established in the PRC on March 15, 2013
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
“H Share(s)”	overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange

DEFINITIONS

“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange (as amended, supplemented or otherwise modified from time to time)
“Main Board”	the stock market (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
“PRC”	the People’s Republic of China excluding, for the purposes of this circular, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“Prospectus”	the prospectus of the Company dated December 16, 2022
“RMB”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the capital of the Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Unlisted Share(s)”	ordinary share(s) issued by the Company with a nominal value of RMB1.00 each and not listed on any stock exchange
“%”	per cent

LETTER FROM THE BOARD



Cryofocus Medtech (Shanghai) Co., Ltd.
康豐生物科技（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6922)

Executive Directors:

Mr. LI Kejian (*Chairman*)
Mr. ZHU Jun
Mr. LIU Wei

*Registered Office, Headquarters and
Principal Place of Business in the PRC:*
Building 15
Lane 3399, Kangxin Road
Pudong New Area
Shanghai
PRC

Non-executive Directors:

Mr. LV Shiwen
Mr. ZHAO Chunsheng

*Principal Place of Business
in Hong Kong:*

Independent Non-executive Directors:

Dr. GAO Dayong
Mr. LIANG Hsien Tse Joseph
Dr. QIN Zheng
Dr. HU Henan

Room 1901, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

April 28, 2026

To the Shareholders

Dear Sir or Madam,

- (1) WORK REPORT OF THE BOARD FOR 2025;**
(2) PROFIT DISTRIBUTION PLAN FOR 2025;
(3) AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR 2025;
(4) 2025 ANNUAL REPORT;
(5) REMUNERATION OF DIRECTORS;
(6) RE-APPOINTMENT OF AUDITORS FOR 2026;
(7) GENERAL MANDATE TO ISSUE SHARES;
AND
(8) NOTICE OF THE AGM

I. INTRODUCTION

The AGM will be convened and held at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC on Friday, June 5, 2026 at 10:00 a.m., the notice of which is set out on pages 10 to 14 of this circular.

LETTER FROM THE BOARD

The purpose of this circular is to provide you with the notice of the AGM and information reasonably necessary to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the AGM.

II. MATTERS TO BE RESOLVED AT THE AGM

At the AGM, ordinary resolutions will be proposed for the approval of, (i) the work report of the Board for 2025 (the “**2025 Work Report of the Board**”); (ii) the profit distribution plan for 2025 (the “**2025 Profit Distribution Plan**”); (iii) the audited consolidated financial statements of the Group for 2025 (the “**2025 Financial Statements**”); (iv) the 2025 Annual Report; (v) the authorization to the Board to determine the remuneration of the Directors; and (vi) the re-appointment of the auditors of the Company for 2026 and the authorization to the Board to determine its remuneration. Further, special resolution will also be proposed for the approval of the grant of a general mandate to the Board to issue Shares.

Ordinary Resolutions

1. *2025 Work Report of the Board*

An ordinary resolution will be proposed at the AGM to approve the 2025 Work Report of the Board. Please refer to the report of the Directors as set out in the 2025 Annual Report.

The 2025 Work Report of the Board was considered and approved by the Board on March 27, 2026 and is hereby proposed at the AGM for consideration and approval.

2. *2025 Profit Distribution Plan*

Based on the operating results, financial position and future development plan of the Company, the Board did not recommend payment of a final dividend for the year ended December 31, 2025.

The 2025 Profit Distribution Plan was considered and approved by the Board on March 27, 2026, and is hereby proposed at the AGM for consideration and approval.

3. *2025 Financial Statements*

Please refer to the audited consolidated financial statements contained in the 2025 Annual Report.

The 2025 Financial Statements were considered and approved by the Board on March 27, 2026, and are hereby proposed at the AGM for consideration and approval.

LETTER FROM THE BOARD

4. 2025 Annual Report

An ordinary resolution will be proposed at the AGM to approve the 2025 Annual Report.

The 2025 Annual Report was considered and approved by the Board on March 27, 2026, and is hereby proposed at the AGM for consideration and approval.

5. Authorization to the Board to determine the remuneration of the Directors

An ordinary resolution will be proposed at the AGM to authorize the Board to determine the remuneration of the Directors.

6. Re-appointment of the auditors of the Company for 2026 and authorization to the Board to determine its remuneration

An ordinary resolution will be proposed at the AGM to consider and approve the re-appointment of Ernst & Young as the external auditors of the Company for 2026 with a term until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine its remuneration.

The estimated audit fee payable to Ernst & Young for the audit of the consolidated financial statements of the Company and its subsidiaries for the financial year ending December 31, 2026 is expected not to exceed RMB2.0 million (exclusive of out-of-pocket expenses).

The estimated audit fee has been determined after due consideration and arm's length negotiations between the Company and Ernst & Young, taking into account, among other things, the size, nature and complexity of the Group's business operations, the expected scope of the audit (covering the consolidated financial statements prepared in accordance with Hong Kong Financial Reporting Standards and Hong Kong Accounting Standards and Interpretations), the audit timetable, and the level and mix of professional staff to be deployed. The estimated audit fee also assumes that there will be no material change in the Group's operations, accounting policies or regulatory environment during the financial year, and that the Company will provide timely and adequate assistance and information as reasonably required for the purposes of the audit.

Unless there is a material change in the basis or assumptions set out above, the final audit fee should not deviate materially from the estimated amount initially disclosed. In the event of any material change, the Company will make further disclosure as appropriate.

LETTER FROM THE BOARD

Special Resolution

7. *Grant of a general mandate to the Board to issue Shares*

To provide more flexibility and convenience to fundraising activities by the Company, the proposal to grant the Board a general mandate is hereby proposed at the AGM for consideration and approval:

A. The Board be granted a general mandate (the “**General Mandate**”), subject to terms and conditions set out in this resolution, for the exercise by the Board during the Relevant Period (as defined below) of powers to allot, issue and/or otherwise deal with additional H Shares and additional Unlisted Shares in the share capital of the Company (“**Additional Shares**”) and/or make offers, agreements or options which might require the issue, allotment and/or dealing with of Additional Shares (such Additional Shares being subject to a maximum of 20% of total number of Shares in issue as at the date of the passing of this resolution), and to make or grant offers or agreements in respect of such Additional Shares:

- i. the General Mandate shall not extend beyond the Relevant Period save that the Board may, during the Relevant Period, make or grant offers or agreements which might require the exercise of such powers after the end of the Relevant Period;
- ii. the total number of Shares approved to be allotted or agreed conditionally or unconditionally to be allotted by the Board shall not exceed 20% of the total number of Shares in issue as at the date of the passing of this resolution, otherwise than pursuant to any scrip dividend scheme or similar arrangement providing for the allotment of such Shares in lieu of the whole or part of a dividend on such Shares in accordance with the Articles of Association;
- iii. the Board will exercise its power under the General Mandate only in accordance with the relevant laws and regulations of the PRC (as amended from time to time) and the Listing Rules and if all necessary filing procedures from the China Securities Regulatory Commission (中國證券監督管理委員會) and/or other relevant PRC government authorities are fulfilled within the time frame required under the relevant laws and regulations in the PRC (as amended from time to time);
- iv. for the purposes of this resolution:

“**H Shares**” means the overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange;

LETTER FROM THE BOARD

“**Relevant Period**” means the period from the passing of this resolution at the AGM until the earlier of:

- (a) the conclusion of the 2026 annual general meeting of the Company following the passing of this resolution; or
- (b) the date on which the authority conferred by this resolution is revoked or varied by a special resolution in a general meeting of the Company;

“**Shares**” means ordinary share(s) in the capital of the Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares;

“**Unlisted Shares**” means the ordinary share(s) issued by the Company with a nominal value of RMB1.00 each and not listed on any stock exchange.

B. Subject to the Board issuing Additional Shares pursuant to this resolution, the Board be authorized to:

- i. approve, execute and do or procure to be executed and done, all documents, deeds and things as it may consider necessary in connection with the issue of such new Shares (including but not limited to time, price, quantity and place of issue, the filing of all necessary filings, registration and applications with or to relevant authorities in the PRC and/or Hong Kong (if applicable), the entering into of an underwriting agreement or any other agreement (if applicable));
- ii. determine the use of proceeds;
- iii. determine the registered capital and the number of Shares pursuant to the issue or allotment of Shares pursuant to this resolution, and register with the relevant authorities in the PRC and/or Hong Kong upon an increase of registered capital and the number of Shares; and
- iv. make corresponding amendments to the Articles of Association as it thinks fit so as to reflect relevant matters such as the registered capital and new capital structure of the Company after the issue and allotment of Shares.

III. AGM

The Company will hold the AGM at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC at 10:00 a.m. on Friday, June 5, 2026 for the Shareholders to consider, and if thought fit, approve the resolutions relating to (i) 2025 Work Report of the Board; (ii) the 2025 Profit Distribution Plan; (iii) the 2025 Financial Statements; (iv) the 2025 Annual Report; (v) the authorization to the Board to determine the remuneration

LETTER FROM THE BOARD

of the Directors; (vi) the re-appointment of the auditors of the Company for 2026 and the authorization to the Board to determine its remuneration; and (vii) the grant of a general mandate to the Board to issue Shares. The notice of the AGM is set out on pages 10 to 14 of this circular.

IV. CLOSURE OF REGISTER OF MEMBERS OF H SHARES AND ASCERTAINING OF ELIGIBILITY OF ATTENDING THE AGM

The register of members of H Shares will be closed from Tuesday, June 2, 2026 to Friday, June 5, 2026, both days inclusive, during which no transfer of H Shares will be registered, in order to determine the holders of the H Shares who are entitled to attend and vote at the AGM.

To be eligible to attend and vote at the AGM, all properly completed transfer documents in respect of H Shares, accompanied by relevant share certificate(s), must be lodged with the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Monday, June 1, 2026 for registration. Shareholders whose names appear on the register of members of the Company on Friday, June 5, 2026 are entitled to attend and vote at the AGM or any adjournment thereof.

V. PROXY FORM

The proxy form for the AGM is enclosed with this circular, and is published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.cryofocus.com).

If you intend to attend the AGM or to appoint a proxy to attend the AGM, you are required to complete and return the proxy form in accordance with instructions printed thereon and return it to the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (in case of holders of H Shares) or the Company's registered office at Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, PRC (in case of holders of Unlisted Shares) as soon as possible and in any event no later than 24 hours before the time fixed for the holding of the AGM or any adjournment thereof (as the case may be) (i.e. no later than 10:00 a.m on Thursday, June 4, 2026 or other date in the event of any adjournment thereof).

Completion and return of the proxy form will not preclude you from attending and voting at the AGM or any adjournment thereof in person if you so wish.

LETTER FROM THE BOARD

VI. VOTING BY WAY OF POLL

In accordance with Rule 13.39(4) of the Listing Rules, any vote of the Shareholders at the AGM must be taken by poll. As such, all the resolutions as set out in the notice convening the AGM will be voted by poll.

No Shareholder will have a material interest in the matters to be approved at the AGM, and will be required to abstain from voting on any resolutions at the AGM.

The announcement of the poll results of the AGM will be published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.cryofocus.com) after the conclusion of the AGM in accordance with the requirements of the Listing Rules.

VII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there is no other matter the omission of which would make any statement in this circular misleading.

VIII. RECOMMENDATIONS

The Directors (including the independent non-executive Directors) consider that all the resolutions as set out in the notice of the AGM are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favor of all the resolutions to be proposed at the AGM.

By order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

NOTICE OF THE AGM



Cryofocus Medtech (Shanghai) Co., Ltd. **康豐生物科技（上海）股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

NOTICE OF THE 2025 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT that the 2025 annual general meeting (the “AGM”) of Cryofocus Medtech (Shanghai) Co., Ltd. (the “Company”) will be held at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the People’s Republic of China (the “PRC”) at 10:00 a.m. on Friday, June 5, 2026, for the purpose of considering, and if thought fit, passing the following resolutions:

ORDINARY RESOLUTIONS

1. To consider and approve the work report of the board (the “Board”) of directors (the “Directors”) of the Company for 2025.
2. To consider and approve the profit distribution plan for 2025.
3. To consider and approve the audited consolidated financial statements of the Company and its subsidiaries for 2025.
4. To consider and approve the annual report of the Company for 2025.
5. To authorize the Board to determine the remuneration of the Directors.
6. To consider and approve the re-appointment of Ernst & Young as the auditors of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine its remuneration.

SPECIAL RESOLUTION

7. To consider and approve the grant of a general mandate (the “General Mandate”) to the Board, subject to terms and conditions set out in this resolution, for the exercise by the Board during the Relevant Period (as defined below) of powers to allot, issue and/or otherwise deal with additional H Shares (as defined below) and additional Unlisted Shares (as defined below) in the share capital of the Company (“Additional Shares”) and/or make offers, agreements or options which might require the issue, allotment and/or dealing with of Additional Shares (such

NOTICE OF THE AGM

Additional Shares being subject to a maximum of 20% of total number of Shares (as defined below) in issue as at the date of the passing of this resolution), and to make or grant offers or agreements in respect of such Additional Shares:

- i. the General Mandate shall not extend beyond the Relevant Period save that the Board may, during the Relevant Period, make or grant offers or agreements which might require the exercise of such powers after the end of the Relevant Period;
- ii. the total number of Shares approved to be allotted or agreed conditionally or unconditionally to be allotted by the Board shall not exceed 20% of the total number of Shares in issue as at the date of the passing of this resolution, otherwise than pursuant to any scrip dividend scheme or similar arrangement providing for the allotment of such Shares in lieu of the whole or part of a dividend on such Shares in accordance with the articles of association of the Company;
- iii. the Board will exercise its power under the General Mandate only in accordance with the relevant laws and regulations of the PRC (as amended from time to time) and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (as amended, supplemented or otherwise modified from time to time) and if all necessary filing procedures with the China Securities Regulatory Commission (中國證券監督管理委員會) and/or other relevant PRC government authorities are fulfilled within the time frame required under the relevant laws and regulations in the PRC (as amended from time to time);
- iv. for the purposes of this resolution:

“**H Shares**” means the overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange;

“**Relevant Period**” means the period from the passing of this resolution at the AGM until the earlier of:

- (a) the conclusion of the 2026 annual general meeting of the Company following the passing of this resolution; or
- (b) the date on which the authority conferred by this resolution is revoked or varied by a special resolution in a general meeting of the Company;

“**Shares**” means ordinary share(s) in the capital of the Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares;

NOTICE OF THE AGM

“**Unlisted Shares**” means the ordinary share(s) issued by the Company with a nominal value of RMB1.00 each and not listed on any stock exchange.

Subject to the Board issuing Additional H Shares and/or Unlisted Shares pursuant to this resolution, the Board be authorized to:

- i. approve, execute and do or procure to be executed and done, all documents, deeds and things as it may consider necessary in connection with the issue of such new Shares (including but not limited to the time, price, quantity and place of issue, the filing of all necessary filings, registration and applications with or to relevant authorities in the PRC and/or Hong Kong (if applicable), the entering into of an underwriting agreement or any other agreement (if applicable));
- ii. determine the use of proceeds;
- iii. determine the registered capital and the number of Shares pursuant to the issue or allotment of Shares pursuant to this resolution, and register with the relevant authorities in the PRC and/or Hong Kong upon an increase of registered capital and the number of Shares; and
- iv. make corresponding amendments to the articles of association of the Company as it thinks fit so as to reflect relevant matters such as the registered capital and new capital structure of the Company after the issue and allotment of Shares.

By order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, April 28, 2026

As at the date of this notice, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.

NOTICE OF THE AGM

Notes:

1. Closure of register of members of H shares of the Company (“H Shares”) and ascertaining of eligibility for attending the AGM

The register of members of H Shares will be closed from Tuesday, June 2, 2026 to Friday, June 5, 2026, both days inclusive, during which no transfer of H Shares will be registered, in order to determine the holders of the H Shares who are entitled to attend and vote at the AGM. To be eligible to attend and vote at the AGM, all properly completed transfer documents in respect of H Shares, accompanied by relevant share certificate(s), must be lodged with the Company’s H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Monday, June 1, 2026 for registration.

2. Proxy

- (1) Each shareholder of the Company entitled to attend and vote at the AGM may appoint one or more proxies in writing to attend and vote at the meeting on his/her behalf. A proxy needs not be a shareholder of the Company.
- (2) The instrument appointing a proxy must be in writing under the hand of the appointor or his/her attorney duly authorized in writing, or if the appointor is a legal entity, either under seal or signed by a director or a duly authorized attorney. If that instrument is signed by an attorney of the appointor, the power of attorney authorizing that attorney to sign or other document of authorization must be notarized.
- (3) To be valid, the proxy form and notarized power of attorney or other document of authorization (if any) must be delivered to the Company’s H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong (in case of holders of H Shares) or the Company’s registered office at Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, PRC (in case of holders of Unlisted Shares) not less than 24 hours before the time fixed for the holding of the AGM or any adjournment thereof (as the case may be) (i.e. no later than 10:00 a.m on Thursday, June 4, 2026 or other date in the event of any adjournment thereof). Completion and return of the proxy form will not preclude the shareholders of the Company from attending and vote at the meeting should they so wish.
- (4) All voting at the AGM shall be taken by way of poll.

3. Registration procedures for attending the AGM

- (1) Shareholders of the Company whose names appear on the register of members of the Company on Friday, June 5, 2026 will be entitled to attend and vote at the AGM or any adjournment thereof.
- (2) A shareholder or his/her proxy should present proof of identity when attending the AGM. If a shareholder is a legal person, its legal representative or other person authorized by the board or other governing body of such shareholder may attend the AGM by providing a copy of the resolution of the board or other governing body of such shareholder appointing such person to attend the AGM.
- (3) Where there are joint holders of any Shares, any one of such joint holders may vote, either in person or by proxy, in respect of such Shares as if he/she/it was solely entitled thereto; but if more than one of such joint holders are present at the AGM, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.
- (4) Shareholders or proxies attending the AGM should state clearly, in respect of each resolution requiring a vote, whether they are voting for or against a resolution. The votes abstained will not be counted in the calculation of the required majority.

4. Voting method at the AGM

According to Rule 13.39(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, any vote of shareholders at a shareholders’ general meeting must be taken by poll. Accordingly, the chairman of the AGM will demand a poll in relation to all the proposed resolutions at the AGM.

NOTICE OF THE AGM

5. Miscellaneous

- (1) The AGM is expected to take no more than half a day. Shareholders who attend the AGM shall bear their own travelling and accommodation expenses.
- (2) The address of the Company's H share registrar is:

Shops 1712–1716, 17th Floor, Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong
- (3) The address and contact details of the Company's registered office is:

Building 15
Lane 3399, Kangxin Road
Pudong New Area
Shanghai
PRC

Telephone: +86 21 209 77850
Email: IR@cryofocus.com
- (4) References to times and dates in this notice are to Hong Kong local times and dates.

6. Arrangements for bad weather

The AGM may be postponed to a later date and/or time or cancelled if the AGM cannot be held due to bad weather. The Company will publish an announcement on the Stock Exchange's website (www.hkexnews.hk) and the Company's website (www.cryofocus.com) to notify shareholders of the Company of the date, time and place of the rescheduled meeting.